Lung cancer is the leading cause of cancer deaths worldwide. Standard chemotherapy has been shown to improve quality of life and has a modest influence on overall survival. This modest improvement in survival is partly due to the choice of chemotherapy regimens that have been based on prognostic factors such as age, performance status and comorbidities of the patient. This underlines the importance of developing a more personalized therapy for patients with non-small cell lung cancer. Such an approach may reduce the variation in how individual patients respond to medications by tailoring therapies to their genetic profile. In this review we focus on several aspects of customized therapy, looking not only at patient characteristics but also to tumor histology and specific tumor biomarkers.
AmitI.WidesR.YardenY. (2007) Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol3: 151–151.
2.
AsmisT.R.DingK.SeymourL.ShepherdF.A.LeighlN.B.WintonT.L. (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol26(1): 54–59.
3.
CappuzzoF.CiuleanuT.StelmakhL.CicenasS.SzczesnaA.JuhaszE. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol11: 521–529.
4.
CeppiP.VolanteM.SaviozziS.RapaI.NovelloS.CambieriA. (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer107: 1589–1596.
5.
CiuleanuT.BrodowiczT.ZielinskiC.KimJ.H.KrzakowskiM.LaackE. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet374: 1432–1440.
6.
CoateL.E.JohnT.TsaoM.S.ShepherdF.A. (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol10: 1001–1010.
7.
DavidoffA.J.TangM.SealB.EdelmanM.J. (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol28: 2191–2197.
8.
EberhardD.A.JohnsonB.E.AmlerL.C.GoddardA.D.HeldensS.L.HerbstR.S. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol23: 5900–5909.
9.
FossellaF.PereiraJ.R.von PawelJ.PluzanskaA.GorbounovaV.KaukelE. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol21: 3016–3024.
10.
GronbergB.H.SundstromS.KaasaS.BremnesR.M.FlottenO.AmundsenT. (2010) Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer46: 2225–2234.
11.
HanahanD.WeinbergR.A. (2000) The hallmarks of cancer. Cell100: 57–70.
12.
HannaN.ShepherdF.A.FossellaF.V.PereiraJ.R.De MarinisF.von PawelJ. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol22: 1589–1597.
13.
HerbstR.S.HeymachJ.V.LippmanS.M. (2008) Lung cancer. N Engl J Med359: 1367–1380.
14.
HongJ.KyungS.Y.LeeS.P.ParkJ.W.JungS.H.LeeJ.I. (2010) Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med25: 294–300.
15.
HornL.PaoW. (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol27: 4232–4235.
16.
IrisaK.MasagoK.TogashiY.FujitaS.HatachiY.FukuharaA. (2010) Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor. Med Oncolin press.
17.
JainR.K. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med7: 987–989.
18.
JohnsonD.H.FehrenbacherL.NovotnyW.F.HerbstR.S.NemunaitisJ.J.JablonsD.M. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol22: 2184–2191.
19.
KwakE.L.BangY.J.CamidgeD.R.ShawA.T.SolomonB.MakiR.G. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med363: 1693–1703.
20.
LafargeS.SylvainV.FerraraM.BignonY.J. (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene20: 6597–6606.
21.
LangerC.J.ManolaJ.BernardoP.KuglerJ.W.BonomiP.CellaD. (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst94: 173–181.
22.
LeeL.CheungW.Y.AtkinsonE.KrzyzanowskaM.K. (2011) Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol29: 106–117.
23.
LilenbaumR.C.HerndonJ.E.IIListM.A.DeschC.WatsonD.M.MillerA.A. (2005) Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol23: 190–196.
24.
LordR.V.BrabenderJ.GandaraD.AlberolaV.CampsC.DomineM. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res8: 2286–2291.
25.
LynchT.J.BellD.W.SordellaR.GurubhagavatulaS.OkimotoR.A.BranniganB.W. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med350: 2129–2139.
26.
Makato et al. (2010).
27.
MaemondoM.InoueA.KobayashiK.SugawaraS.OizumiS.IsobeH. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med362: 2380–2388.
28.
MitsudomiT.MoritaS.YatabeY.NegoroS.OkamotoI.TsurutaniJ. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol11: 121–128.
29.
Mitsudomi et al. (2009).
30.
Mok et al. (2009).
31.
MonicaV.ScagliottiG.V.CeppiP.RighiL.CambieriA.Lo IaconoM. (2009) Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clin Cancer Res15: 7547–7552.
32.
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J311: 899–909.
33.
OlaussenK.A.DunantA.FouretP.BrambillaE.AndreF.HaddadV. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med355: 983–991.
34.
PaezJ.G.JanneP.A.LeeJ.C.TracyS.GreulichH.GabrielS. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304: 1497–1500.
35.
PaoW.MillerV.ZakowskiM.DohertyJ.PolitiK.SarkariaI. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A101: 13306–13311.
36.
PaoW.MillerV.A. (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol23: 2556–2568.
37.
PrestaL.G.ChenH.O'ConnorS.J.ChisholmV.MengY.G.KrummenL. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res57: 4593–4599.
38.
ReckM.von PawelJ.ZatloukalP.RamlauR.GorbounovaV.HirshV. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol27: 1227–1234.
39.
ReckM.von PawelJ.ZatloukalP.RamlauR.GorbounovaV.HirshV. (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol21: 1804–1809.
40.
RighiL.PapottiM.G.CeppiP.BilleA.BacilloE.MolinaroL. (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol28: 1534–1539.
41.
RosellR.DanenbergK.D.AlberolaV.BeplerG.SanchezJ.J.CampsC. (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res10: 1318–1325.
42.
RosellR.MoranT.QueraltC.PortaR.CardenalF.CampsC. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med361: 958–967.
43.
RosellR.SkrzypskiM.JassemE.TaronM.BartolucciR.SanchezJ.J. (2007) BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One2: e1129–e1129.
44.
RuschV.KlimstraD.VenkatramanE.PistersP.W.LangenfeldJ.DmitrovskyE. (1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res3: 515–522.
45.
SandlerA.GrayR.PerryM.C.BrahmerJ.SchillerJ.H.DowlatiA. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med355: 2542–2550.
46.
ScagliottiG.V.ParikhP.von PawelJ.BiesmaB.VansteenkisteJ.ManegoldC. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol26: 3543–3551.
47.
SculierJ.P.ChanskyK.CrowleyJ.J.Van MeerbeeckJ.GoldstrawP. (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol3: 457–466.
48.
ShawA.T.YeapB.Y.Mino-KenudsonM.DigumarthyS.R.CostaD.B.HeistR.S. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol27: 4247–4253.
49.
ShepherdF.A.Rodrigues PereiraJ.CiuleanuT.TanE.H.HirshV.ThongprasertS. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med353: 123–132.
50.
ShihC.HabeckL.L.MendelsohnL.G.ChenV.J.SchultzR.M. (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul38: 135–152.
51.
SigmondJ.BackusH.H.WoutersD.TemminkO.H.JansenG.PetersG.J. (2003) Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol66: 431–438.
52.
SimonG.R.SharmaS.CantorA.SmithP.BeplerG. (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest127: 978–983.
53.
SodaM.ChoiY.L.EnomotoM.TakadaS.YamashitaY.IshikawaS. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature448: 561–566.
54.
SodaM.TakadaS.TakeuchiK.ChoiY.L.EnomotoM.UenoT. (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A105: 19893–19897.
55.
ThomsonS.PettiF.Sujka-KwokI.EpsteinD.HaleyJ.D. (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis25: 843–854.
56.
TsaoM.S.SakuradaA.CutzJ.C.ZhuC.Q.Kamel-ReidS.SquireJ. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med353: 133–144.
57.
VogelzangN.J.RusthovenJ.J.SymanowskiJ.DenhamC.KaukelE.RuffieP. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol21: 2636–2644.
58.
WangB.MatsuokaS.BallifB.A.ZhangD.SmogorzewskaA.GygiS.P. (2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science316: 1194–1198.
59.
WeissG.J.LangerC.RosellR.HannaN.ShepherdF.EinhornL.H. (2006) Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol24: 4405–4411.
60.
WillettC.G.BoucherY.di TomasoE.DudaD.G.MunnL.L.TongR.T. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med10: 145–147.
61.
WillettC.G.DudaD.G.di TomasoE.BoucherY.CzitoB.G.VujaskovicZ. (2007) Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol4: 316–321.
